Skip to main content
Fig. 4 | Virology Journal

Fig. 4

From: A novel cocktail therapy based on quintuplet combination of oncolytic herpes simplex virus-2 vectors armed with interleukin-12, interleukin-15, GM-CSF, PD1v, and IL-7 × CCL19 results in enhanced antitumor efficacy

Fig. 4

Therapeutic effects of mono virus and 5voHSV2 treatment in a CT26 Model. Balb/c mice were subcutaneously implanted with CT26 tumor cells and intratumorally inoculated with OVs on days 0, 3, 6 (n = 8–10 per group). A Schematic depiction of the experiment. B The tumor volume growth curves of the OVs and mock-treated groups, the data are shown as mean + SD. ***P < 0.001, ****P < 0.0001 (vs 5voHSV2 group) by repeated-measures 2-way ANOVA with Bonferroni’s correction. C Mouse PBMC killing of CT26-GFP tumor cells. CT26-GFP cells were seeded in the 96-well plate overnight. Then infected with blank control, oHSV2-IL12, -PD1v, -IL15, -IL7 × CCL19, GM-CSF, and 5voHSV2 (MOI = 0.1). PBMC were added with effector cells:target cells ratio being 2:1 for another 60 h. The killing activity was recorded with the PerkinElmer Operetta imaging system

Back to article page

Virology Journal

ISSN: 1743-422X